Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Norway / NCT01538550
Active, not recruiting Not applicable

Pilot Study of a National Screening Programme for Bowel Cancer in Norway

NCT01538550 · tracked via the Priya Life Science Norway tracker
Sponsor
Norwegian Institute of Public Health
Phase
Not applicable
Started
2012-03
Last updated
2026-04-14

Condition(s) studied

Colorectal CancerColorectal Adenomas

Investigational drug(s) / intervention(s)

Flexible sigmoidoscopyiFOBT

Flexible sigmoidoscopy: Flexible sigmoidoscopy screening is offered once only

iFOBT: Biennial screening with iFOBT

Study summary

The Norwegian government has funded a pilot study of a national colorectal cancer screening programme. This implies initiation of a screening pilot in the catchment area for two hospitals in Norway. The target population is average risk men and women at age 50-74 years. The programme is designed as a comparative effectiveness programme evaluating acceptance and test performance for two screening methods - fecal occult blood testing (FOBT) and flexible sigmoidoscopy (FS). This protocol describes the main methodological issues, necessary resources and the expected effects.

Eligibility

Sex
ALL
Min age
50 Years
Max age
74 Years
Healthy volunteers
No
Inclusion Criteria: * men and women * age 50-74 years * living in defined geographic areas in South-East Norway (catchment areas for two hospitals) Exclusion Criteria: * previous colorectal cancer

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Moss Hospital Oslo Norway
Bærum County Hospital Rud Norway

More Norwegian Institute of Public Health trials in Norway

Classroom Air Purifiers for Reducing School Absence Enrolling by invitation
Effects of the 5 Ways to Wellbeing Course Effects of the 5 Ways to Wellbeing Course Recruiting
NORCCAP: Norwegian Colorectal Cancer Prevention Trial Active, not recruiting
Targeting Lifestyle to Improve Colorectal Cancer Screening Starting soon
Artificial Intelligence in Mammography Screening in Norway Recruiting

Other trials for the same condition

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer Recruiting
NORCCAP: Norwegian Colorectal Cancer Prevention Trial Active, not recruiting
Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation Active, not recruiting
The Northern-European Initiative on Colorectal Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01538550 on ClinicalTrials.gov ↗ ← All trials in Norway